Published by Iain Gilbert on 13th February 2026
(Sharecast News) - Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's near‑term earnings outlook looked less favourable despite what it called "exceptional" R&D delivery.
URL: http://www.digitallook.com/dl/news/story/35699255/...